Listar por tema "Multiple Sclerosis"

Ordenar por:Orden:Resultados:

  • Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management 
    Carrá, A.; Macías Islas, M.A.; Tarulla, A.; Bichuetti, D.B.; Finkelsztejn, A.; Dadalti Fragoso, Y.; Árcega-Revilla, R.; Cárcamo Rodríguez, C.; Durán, J.C.; García Bonitto, J.; León, Rosalba; Oehninger Gatti, C.; Orozco, G.; Vizcarra-Escobar, Darwin (Taylor and Francis, 2015)
    Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and ...
  • CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis 
    Menezes, Soraya Maria; Decanine, Daniele; Brassat, David; Khouri, Ricardo; Schnitman, Saul V.; Kruschewsky, Ramon; López, Giovanni; Alvarez, Carolina; Talledo Albujar, Michael John; Gotuzzo Herencia, José Eduardo; Vandamme, Anne-Mieke; Galvão-Castro, Bernardo; Liblau, Roland; Weyenbergh, Johan Van (BioMed Central, 2014)
    Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no ...
  • Treatment issues in multiple sclerosis in Latin America 
    Vizcarra-Escobar, Darwin; Mendiola-Yamasato, A.; Anculle-Arauco, V.; Vizcarra-Pasapera, J.; Guillen-Mendoza, Daniel (Karger, 2015)
    Treatment issues of multiple sclerosis (MS) in Latin America (LA) have recently been addressed. Some particular features of the health systems, patients and medical providers are scarcely described. Moreover, LA patients ...

Buscar en el Repositorio

Listar

Panel de Control